Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Description
INTRODUCTION: The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein
